Effects of an energy‐restricted low‐carbohydrate, high unsaturated fat/low saturated fat diet versus a high‐carbohydrate, low‐fat diet in type 2 diabetes: A 2‐year randomized clinical trial

Diabetes, Obesity and Metabolism - Tập 20 Số 4 - Trang 858-871 - 2018
Jeannie Tay1,2,3, Campbell H. Thompson3, Natalie D. Luscombe‐Marsh2, Thomas P. Wycherley4, Manny Noakes2, Jonathan D. Buckley4, Gary Wittert3, William S. Yancy5,6, Grant D. Brinkworth2
1Agency for Science, Technology and Research (A-STAR) Singapore
2Commonwealth Scientific and Industrial Research Organisation (CSIRO) – Health and Biosecurity, Adelaide, Australia
3Discipline of Medicine, University of Adelaide, Adelaide, Australia
4Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, University of South Australia, Adelaide, Australia
5Center for Health Services Research in Primary Care, Veterans Affairs Medical Center, Durham, North Carolina
6Division of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina

Tóm tắt

AimTo examine whether a low‐carbohydrate, high‐unsaturated/low‐saturated fat diet (LC) improves glycaemic control and cardiovascular disease (CVD) risk factors in overweight and obese patients with type 2 diabetes (T2D).MethodsA total of 115 adults with T2D (mean [SD]; BMI, 34.6 [4.3] kg/m2; age, 58 [7] years; HbA1c, 7.3 [1.1]%) were randomized to 1 of 2 planned energy‐matched, hypocaloric diets combined with aerobic/resistance exercise (1 hour, 3 days/week) for 2 years: LC: 14% energy as carbohydrate, 28% as protein, 58% as fat (<10% saturated fat); or low‐fat, high‐carbohydrate, low‐glycaemic index diet (HC): 53% as CHO, 17% as protein, 30% as fat (<10% saturated fat). HbA1c, glycaemic variability (GV), anti‐glycaemic medication effect score (MES, calculated based on the potency and dosage of diabetes medication), weight, body composition, CVD and renal risk markers were assessed before and after intervention.ResultsA total of 61 (LC = 33, HC = 28) participants completed the study (trial registration: http://www.anzctr.org.au/, ANZCTR No. ACTRN12612000369820). Reductions in weight (estimated marginal mean [95% CI]; LC, −6.8 [−8.8,−4.7], HC, −6.6 [−8.8, −4.5] kg), body fat (LC, −4.3 [−6.2, −2.4], HC, −4.6 [−6.6, −2.7] kg), blood pressure (LC, −2.0 [−5.9, 1.8]/ −1.2 [−3.6, 1.2], HC, −3.2 [−7.3, 0.9]/ −2.0 [−4.5, 0.5] mmHg), HbA1c (LC, −0.6 [−0.9, −0.3], HC, −0.9 [−1.2, −0.5] %) and fasting glucose (LC, 0.3 [−0.4, 1.0], HC, −0.4 [−1.1, 0.4] mmol/L) were similar between groups (P ≥ 0.09). Compared to HC, the LC achieved greater reductions in diabetes medication use (MES; LC, −0.5 [−0.6, −0.3], HC, −0.2 [−0.4, −0.02] units; P = 0.03), GV (Continuous Overall Net Glycemic Action calculated every 1 hour (LC, −0.4 [−0.6, −0.3], HC, −0.1 [−0.1, 0.2] mmol/L; P = 0.001), and 4 hours (LC, −0.9 [−1.3, −0.6], HC, −0.2 [−0.6, 0.1] mmol/L; P = 0.02)); triglycerides (LC, −0.1 [−0.3, 0.2], HC, 0.1 [−0.2, 0.3] mmol/L; P = 0.001), and maintained HDL‐C levels (LC, 0.02 [−0.05, 0.1], HC, −0.1 [−0.1, 0.01] mmol/L; P = 0.004), but had similar changes in LDL‐C (LC, 0.2 [−0.1, 0.5], HC, 0.1 [−0.2, 0.4] mmol/L; P = 0.85), brachial artery flow mediated dilatation (LC, −0.5 [−1.5, 0.5], HC, −0.4 [−1.4, 0.7] %; P = 0.73), eGFR and albuminuria.ConclusionsBoth diets achieved comparable weight loss and HbA1c reductions. The LC sustained greater reductions in diabetes medication requirements, and in improvements in diurnal blood glucose stability and blood lipid profile, with no adverse renal effects, suggesting greater optimization of T2D management.

Từ khóa


Tài liệu tham khảo

10.2337/dc13-2042

10.1111/j.1464-5491.2011.03371.x

10.1136/bmjdrc-2016-000354

10.3945/ajcn.112.042457

10.7326/0003-4819-140-10-200405180-00007

10.7326/0003-4819-153-3-201008030-00005

10.1001/jama.297.9.969

10.2337/dc11-2216

10.1016/j.nut.2014.06.011

American Diabetes Association, 2017, Standards of Medical Care in Diabetes‐2017, Diabetes Care, 40, S1

10.1056/NEJMoa0708681

10.1007/s00125-012-2567-4

10.1146/annurev-nutr-121214-104422

10.3945/ajcn.115.112581

10.2337/dc14-0845

10.1097/MD.0000000000002181

Schofield WN, 1985, Predicting basal metabolic rate, new standards and review of previous work, Hum Nutr Clin Nutr, 39, 5

10.1111/dom.12191

10.1093/clinchem/18.6.499

10.1016/j.jacl.2008.06.013

10.2337/diacare.27.6.1487

10.1016/j.atherosclerosis.2016.07.908

10.7326/0003-4819-150-9-200905050-00006

10.1093/ajcn/25.5.539

Tudor‐Locke C, 2012, A catalog of rules, variables, and definitions applied to accelerometer data in the National Health and Nutrition Examination Survey, 2003‐2006, Prev Chronic Dis, 9

10.1186/1743-7075-5-36

10.1056/NEJMoa022207

10.1001/jama.293.1.43

10.1159/000187054

10.1016/0002-9343(88)90310-5

10.1016/S0140-6736(98)07019-6

10.1016/S0140-6736(10)60576-4

10.1056/NEJMoa0802987

Callaghan BC, 2012, Enhanced glucose control for preventing and treating diabetic neuropathy, Cochrane Database Syst Rev, 6

10.1056/NEJMoa1001288

10.1056/NEJMoa0802743

10.2337/diacare.27.6.1458

10.2337/db15-0084

10.1038/ncpendmet1066

10.1136/bmj.316.7134.823

10.1056/NEJMoa1200303

10.1016/j.jacc.2007.11.044

National Institutes of Health/ National Heart LaBI, 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults‐‐the evidence report. National Institutes of Health, Obes Res, 6, 51S

10.1001/jama.2016.7602

10.1002/oby.20662

10.1146/annurev.nutr.21.1.323

10.1001/archinternmed.2009.492

10.2337/dc08-2108

10.7326/M14-0180

10.1001/jama.2009.726

10.1186/1743-7075-10-3

10.2337/diacare.21.12.2180

10.1093/ajcn/86.2.276

10.1001/jama.281.21.2005